Clinical trial · Observational
Performance of Spectral CT-scan in Patients With Metastatic Colorectal Cancer: a Prospective Multicentre Study
NCT06024837CI-TRIAL-00080902recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Spectral CT is a rapidly expanding imaging modality that allows a reduction in iodine dose and irradiation compared to conventional scanning. It uses the difference in attenuation of the material according to the two different energy levels of the incident x-ray beams. The dual-energy scanner has a wide range of clinical applications, particularly in abdominal imaging.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colo-rectal Cancer | Colon Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CT Images | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Patients with Colo-rectal Cancer
- description
- Patients with Colo-rectal Cancer will be included.
- interventionNames
- Other: CT Images
Primary outcomes (2)
- measure
- Comparison of peritoneal lesion mapping between spectral scanning and conventional scanning
- timeFrame
- Year : 1
- description
- Comparison of peritoneal lesion mapping between spectral scanning (monoenergetic acquisitions, iodine mapping, etc.) and conventional scanning (acquisition obtained during spectral acquisition).
- measure
- Comparison of hepatic lesion mapping between spectral scanning and conventional scanning
- timeFrame
- Year : 1
- description
- Comparison of hepatic lesion mapping between spectral scanning (monoenergetic acquisitions, iodine mapping, etc.) and conventional scanning (acquisition obtained during spectral acquisition).
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Patients followed for colorectal cancer with synchronous or metachronous liver metastases and/or peritoneal carcinosis * Patients with a curative surgical resection plan Exclusion Criteria: * Patients with non-metastatic colorectal cancer * Patients treated with chemotherapy without surgical plans * Patients with colorectal cancer with extra-hepatic and extra-peritoneal metastases alone (e.g. lung, bone)
References
Publications (0)
Data not yet available
No reference posted for this study.